Leukemia & lymphoma

Rank: Unranked / 33517
Indexings
ncbi ulakbim sci
Short Name Leuk Lymphoma
Abbreviated Name leuk lymphoma
ISSN 1029-2403
Aim and Scope
URL
Author Instructions

Journal Metrics & Performance

Performance Statistics
8
Total Articles
0
Recent Articles
212.1
Average Citations
308
Total Views
1029-2403
ISSN
Quality Scores
Quality Scores: Not Calculated

Quality metrics are being calculated for this journal.

Sign in to calculate quality scores

Publications Per Year

Recent Articles (8 total)

2020
Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.
Vol. 61 , No. 1 , pp. 91-97
272 views DOI Abstract
2020
Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
Vol. 61 , No. 1 , pp. 176-180
271 views DOI
2019
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'
Vol. 60 , No. 14 , pp. -
241 views Abstract
2018
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Vol. 59 , No. 6 , pp. 1514-1516
241 views DOI
2013
Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
Vol. 54 , No. 5 , pp. 1042-7
231 views DOI Abstract
2019
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)
Vol. 60 , No. 12 , pp. -
199 views Abstract
2017
Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia.
Vol. 58 , No. 7 , pp. 1726-1729
161 views DOI
2022
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
, pp. 1-12
81 views DOI Abstract